Clinical Trial: Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07004712) titled 'Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer' on May 13.

Brief Summary: This study is an open, single-arm, single-center phase II clinical study, which aims to evaluate the efficacy and safety of adebelizumab combined with irinotecan liposome in the second-line treatment of advanced small cell lung cancer, explore biomarkers to predict the efficacy, and further select the dominant population in immunotherapy.

In this study, 46 patients with extensive SCLC who had previously received immunotherapy combined with chemotherapy were enrolled. Sub...